Materialise NV (MTLS)
Materialise NV (MTLS) Q2 2026 Earnings Call Transcript
Materialise NV (MTLS) Q2 2026 Earnings Call Transcript
Materialise Q2 Earnings Call Highlights
Materialise NASDAQ: MTLS reported second-quarter revenue growth of more than 8% year over year to €70.1 million, driven by double-digit expansion in its Medical segment and continued improvement in profitability. The company raised its full-year adjusted EBIT outlook while maintaining its revenue guidance, despite the anticipated revenue effect of divesting its RapidFit and Eyewear businesses.
All You Need to Know About Materialise (MTLS) Rating Upgrade to Buy
Materialise (MTLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Investors Undervaluing Materialise (MTLS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Materialise Q1 Earnings Call Highlights
Materialise NASDAQ: MTLS reported first-quarter 2026 revenue of EUR 66.3 million, which Chief Financial Officer Koen Berges said was stable year-over-year despite “significant foreign exchange headwinds,” primarily tied to a weaker U.S. dollar. Gross profit rose to EUR 37.9 million and gross margin expanded to 57.2%, helping drive improved profitability and positive free cash flow during the period.
Materialise NV (MTLS) Q1 2026 Earnings Call Transcript
Materialise NV (MTLS) Q1 2026 Earnings Call Transcript
Materialise: The Medical Segment Alone Makes This A Buy
Materialise receives a 'Buy' rating, driven by robust growth in its medical segment despite weakness in software and manufacturing. MTLS's medical segment boasts a 4-year CAGR of 16%, with management guiding for continued strong growth through FY2026. The company maintains a fortress balance sheet with €71m net cash and trades at a significant discount to sector peers on EV/Sales and EV/EBITDA.
Materialise: Medical And Software-Led Rebound
Materialise is poised for a return to consistent growth and improving margins, led by Medical strength and stabilization of its Software business. The Manufacturing segment faces ongoing headwinds, but expansion into aerospace and defense could create a modest rebound over the next few years. The combination of a low valuation, consistent growth, and higher margins should lead the stock higher, which will be supported by a share buyback program.
Materialise NV (MTLS) Q4 2025 Earnings Call Transcript
Materialise NV (MTLS) Q4 2025 Earnings Call Transcript
Materialise (MTLS) Upgraded to Strong Buy: What Does It Mean for the Stock?
Materialise (MTLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for Dec. 18: MTLS, AMX, and More
JRVR, CALX, MTLS, AMX and NWFL have been added to the Zacks Rank #1 (Strong Buy) List on Dec. 18, 2025.
Materialise: Still Treading Water, Remains Cash Flow Positive
Materialise's Manufacturing segment continues to face headwinds, driven by exposure to areas like prototyping, automotive, and Europe. Materialise's Medical segment continues to perform well, and the Software segment appears set to rebound in coming quarters. Despite macro challenges, Materialise remains cash flow positive and has a strong net cash position.
